Delivered by Mr Barry O'Leary, Chief Executive Officer, IDA Ireland at the IPHA Annual Meeting 2010

1. Irish Pharmaceutical
Healthcare Association (IPHA)
Annual Meeting
Barry O’Leary
November 25th 2010

2. Current Impact of FDI
gh
KEY FDI IMPACTS ON THE IRISH
ECONOMY
- €110 BN Exports
- 240,000 Jobs in Total
- 55% of Corporation Tax
- €19 BN Expenditure
- €7 BN Payroll
- 73% of Business RD&I expenditure
WORLD LEADERS CHOOSE IRELAND
- 8 of the top 10 in ICT
- 8 of the top 10 in Pharmaceuticals
- 15 of the top 25 in Medical Devices
- More than 50% of the world’s leading
Financial Services firms

3. • Global Services
• High-end Manufacturing
• Research, Development & Innovation
Business Model Focus
Sectors
• Life Sciences - Pharma/Biopharma &
- Medical Devices
• Information & Communications Technology
• Financial Services
• Content Industry, Consumer & Business
Services
• Diversified Industries and Engineering
• CleanTech
IDA Focus

4. FDI 2010 – Recent Wins
Existing Clients

5. FDI Recent Wins – New Clients

6. Ireland – major Life Sciences Hub
Biopharma Med Tech
Healthcare
Services
• 8 0f the top 10 Pharma
• 8 of top 10 and 15 of top 25
Medical Technologies
• 44,000 jobs
• Exports €51 Bn p.a.
• Numerous sub-suppiier and
service providers

7. Recent Lifesciences FDI
Investments
Investing €220m in a new fill finish vaccines facility (170 jobs)
Carlow. EMEA Service Centre in Dublin (150 Jobs).
EMEA Shared Services for 100 people, Cork.
Biologics, €400m investment.
Investing over €160m in R&D in Galway, Cork and Clonmel
Global manufacturing and development, 204 people, Dundalk
100 person manufacturing expansion in Co. Galway
250 person manufacturing expansion in Ballina
€30m investment in bio-analytical / chemistry services, 250 Jobs in Athlone
Expansion of €130m and 170 new jobs
European Shared Services Centre in Cork - 30 jobs
European Services Centre in Dublin, creating more than 200 job.
€50 million new manufacturing investment, creating 250 jobs in Clare

8. Global Lifesciences Industry
Drivers/Challenges
Pharma
• Patent cliff – increased
generics
• Pipeline Challenge
• Restructuring to
accommodate new reality
– M&A, cost reduction
• Increasing Regulatory
hurdles and costs
• US Healthcare reform –
biosimilars pathway
• Biologics
• Rise of Asia
• Ageing population
• Healthcare reform tax
• 510K regulatory pathway
changes USA
• Convergence – clear
coupling of devices and
tech.
• Asian market growing
strongly

9. 9
Ageing population
20%+ of population will be over 65 in
developed markets by 2025
Emerging markets
Pharma market expected to double by 2015
Unmet needs
Oncology, immunology, antiviral HIV, stroke,
Alzheimer's, obesity, thrombosis, HCV
New technologies
e.g., Predictive technologies, such as
biomarkers, in silico models
Increasing
demand
Demand for healthcare to continue to grow
Broader
offer
1. Source : IMS Market prognosis
Copyright©2010byTheBostonConsultingGroup,Inc.Allrightsreserved.

10. Evolution of Pharma Bio
• Single Platform Technology
• API manufacturing
• Q&A labs
• Sophisticated
manufacturing
• Liquids
• Tabletting
• Creams
• Patches
• Molecular
diagnostics
• Reference
Global Sites
• Biopharma
• Shared
services -
Supply chain,
Regulatory,
Finance
• Commodity
medicines
• Self-Dx, Self
Treat
• Nutraceuticals
• Convergent
technologies
• Connected
Health
• Personalised
Medicine
• Combination
medical
products
• Medical Services
1980s 1990s 2000s 2020

11. 11
Horizon 2020 - Ongoing Evolution of Pharma Bio
2010-2015- Capturing and Delivering marketplace opportunites
• Integrating disease with lifestyle management
• Leveraging expertise in nutraceuticals, point of care assays
• Advancing molecular diagnostics and targetted therapies
• Utilising genetic testing & biomarkers in advanced clinical trials
• Developing convergent medical products
• Rise of bioinfomatics, population health strategies
Now - Building and Developing the sector
• Winning new biopharma investments
• Leveraging NiBRT to advance Biopharma Industry
• Enhancing Ireland’s small molecule Value Proposition
• Support vaccine development, generic reformulation, improved drug delivery
• Expanding mandates of top 30 companies “start earlier-finish later”
• Supporting new starts in packaging, tabletting, labelling, supply chain
• Expanding footprints into shared services, commercialisation, clinical trials

12. 12
Horizon 2020 - Ongoing Evolution of Pharma Bio
2020 Foresight
• Convergent medical management – drug & dynamic device
• Regenerative Health platforms in ageing, organ, joint replacement
• Connected Health platforms integrating e-health
• Cancer vaccines, targeted personal therapies
• Advancing silver care, aged care, focus on mental wellness
• Tailored health insurance per decade of life
• Development of “polypill”
• Integrated digital medical record and decision support
• Remote monitoring and treatment at home
• New bioactive materials and molecules from marine ecosystem

13. Ireland : A Proven Location for
Lifesciences Service Activities

14. Initiatives to protect and grow Industry
• Transformation –
– Technology uplift,
– Skills uplift
– Process development
– Product Development
– Energy Efficiency
– Operational excellence
• Strategic Sites and CMO
• NIBRT for Bio
• National Commercialisation centre for medical devices
• National competence centre for small molecule production
• International healthcare services centre
• Healthcare Innovation hub with HSE
• Research and Development Agenda

15. • TV Ads
• Live TV Interviews
• Online Media
• Print Media
• Airport Posters
• Press Interviews
• Web Optimisation
Integrated Communications Campaign

17. Professor Luke O’Neill – Trinity College Dublin

20. IDA TV Ad – 30 Secs

21. Thank You